BR112022026534A2 - Métodos e composições para editar o locus b2m em células b - Google Patents
Métodos e composições para editar o locus b2m em células bInfo
- Publication number
- BR112022026534A2 BR112022026534A2 BR112022026534A BR112022026534A BR112022026534A2 BR 112022026534 A2 BR112022026534 A2 BR 112022026534A2 BR 112022026534 A BR112022026534 A BR 112022026534A BR 112022026534 A BR112022026534 A BR 112022026534A BR 112022026534 A2 BR112022026534 A2 BR 112022026534A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- modified
- methods
- compositions
- locus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 5
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 3
- 210000002865 immune cell Anatomy 0.000 abstract 3
- 101150076800 B2M gene Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Document Processing Apparatus (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Crystallography & Structural Chemistry (AREA)
Abstract
MÉTODOS E COMPOSIÇÕES PARA EDITAR O LOCUS B2M EM CÉLULAS B. Algumas concretizações dos métodos e composições aqui fornecidas incluem a preparação de células B modificadas. Em algumas concretizações, um gene endógeno de microglobulina beta-2 (B2M) em uma célula B é modificado. Algumas concretizações se referem ao aumento da resistência de células B modificadas à morte por células imunes alogênicas. Em algumas concretizações, o gene B2M endógeno é inativado aumentando a resistência da célula B modificada à morte por células imunes alogênicas. Em algumas concretizações, um MHC-I de substituição é inserido em um gene B2M endógeno inativado, aumentando a resistência da célula B modificada à morte por células imunes alogênicas. Algumas concretizações incluem enriquecimento para células modificadas com sucesso.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047978P | 2020-07-03 | 2020-07-03 | |
US202063114131P | 2020-11-16 | 2020-11-16 | |
PCT/US2021/039953 WO2022006309A1 (en) | 2020-07-03 | 2021-06-30 | Methods and compositions for editing the b2m locus in b cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026534A2 true BR112022026534A2 (pt) | 2023-04-18 |
Family
ID=79315579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026534A BR112022026534A2 (pt) | 2020-07-03 | 2021-06-30 | Métodos e composições para editar o locus b2m em células b |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4175651A1 (pt) |
JP (1) | JP2023532917A (pt) |
KR (1) | KR20230035048A (pt) |
CN (1) | CN116033910A (pt) |
AU (1) | AU2021300358A1 (pt) |
BR (1) | BR112022026534A2 (pt) |
CA (1) | CA3186620A1 (pt) |
IL (1) | IL299491A (pt) |
MX (1) | MX2022015788A (pt) |
WO (1) | WO2022006309A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024030857A1 (en) * | 2022-08-01 | 2024-02-08 | Idexx Laboratories, Inc. | Human mouse fractional abundance assays |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
EP3645036A1 (en) * | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
-
2021
- 2021-06-30 WO PCT/US2021/039953 patent/WO2022006309A1/en active Application Filing
- 2021-06-30 AU AU2021300358A patent/AU2021300358A1/en active Pending
- 2021-06-30 EP EP21832140.4A patent/EP4175651A1/en active Pending
- 2021-06-30 CA CA3186620A patent/CA3186620A1/en active Pending
- 2021-06-30 JP JP2022581341A patent/JP2023532917A/ja active Pending
- 2021-06-30 MX MX2022015788A patent/MX2022015788A/es unknown
- 2021-06-30 CN CN202180047549.4A patent/CN116033910A/zh active Pending
- 2021-06-30 IL IL299491A patent/IL299491A/en unknown
- 2021-06-30 KR KR1020237001885A patent/KR20230035048A/ko unknown
- 2021-06-30 BR BR112022026534A patent/BR112022026534A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230035048A (ko) | 2023-03-10 |
EP4175651A1 (en) | 2023-05-10 |
CA3186620A1 (en) | 2022-01-06 |
MX2022015788A (es) | 2023-02-27 |
IL299491A (en) | 2023-02-01 |
JP2023532917A (ja) | 2023-08-01 |
WO2022006309A1 (en) | 2022-01-06 |
AU2021300358A1 (en) | 2023-02-02 |
CN116033910A (zh) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7294838B2 (ja) | Hla g改変された細胞および方法 | |
Bailey-Bucktrout et al. | Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response | |
RU2720934C2 (ru) | Последовательности 3'-utr для стабилизации рнк | |
Glas et al. | The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. | |
Benati et al. | CRISPR/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient | |
US20190309269A1 (en) | Therapeutic cell systems and methods for treating hyperuricemia and gout | |
BR112022026534A2 (pt) | Métodos e composições para editar o locus b2m em células b | |
BR112019014257A2 (pt) | método para gerar uma célula-tronco pluripotente hipoimunogênica, célula-tronco pluripotente hipoimunogênica humana, método para produzir uma célula pluripotente hipoimunogênica, e ss-2 microglobulina | |
BR112022000641A2 (pt) | Modificação genética de célula efetora imune e uso da mesma | |
TW202140784A (zh) | 用於調節基因表現的安全開關 | |
Sofi et al. | Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease | |
BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
Ochel et al. | Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes | |
CN107846903A (zh) | 胎盘来源的干细胞及其用于恢复再生引擎、纠正蛋白质组缺陷并延长衰老个体寿命的用途 | |
EP1932537A1 (en) | Expression of transgenic T cell receptors in LAK-T cells | |
Hong et al. | Antigen presentation by individually transferred HLA class I genes in HLA-A, HLA-B, HLA-C null human cell line generated using the multiplex CRISPR-Cas9 system | |
WO2020117852A1 (en) | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use | |
PT84640B (pt) | Vector viral que contem um gene que codifica para uma das glicoproteinas (gp) do involucro do virus responsavel pela s.i.d.a. e anticorpos contra essas glicoproteinas | |
Crivello et al. | Multiple knockout of classical HLA class II β-chains by CRISPR/Cas9 genome editing driven by a single guide RNA | |
EP3912644A1 (en) | Therapeutic agent for dystrophic epidermolysis bullosa | |
Creusot et al. | Concise review: cell-based therapies and other non-traditional approaches for type 1 diabetes | |
Lo et al. | Inhibiting TLR7 expression in the retinal pigment epithelium suppresses experimental autoimmune uveitis | |
CN116323921A (zh) | 从人多能干细胞生成cd4+效应t细胞和调节性t细胞 | |
Ksander et al. | Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes | |
CN111575306B (zh) | 一种激活红细胞中γ珠蛋白基因表达的方法 |